Last reviewed · How we verify
using ncid database to assess the safety of olaparib in chinese patients with ovarian cancer by examining the incidence seriousness and severity of all ae
Approved treatments
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- using ncid database to assess the safety of olaparib in chinese patients with ovarian cancer by examining the incidence seriousness and severity of all ae patent landscape — cliff calendar, originator estates, attackable patents
- using ncid database to assess the safety of olaparib in chinese patients with ovarian cancer by examining the incidence seriousness and severity of all ae treatment landscape brief
- using ncid database to assess the safety of olaparib in chinese patients with ovarian cancer by examining the incidence seriousness and severity of all ae treatment updates RSS
Related
- Treatment landscape: using ncid database to assess the safety of olaparib in chinese patients with ovarian cancer by examining the incidence seriousness and severity of all ae patent cliff · using ncid database to assess the safety of olaparib in chinese patients with ovarian cancer by examining the incidence seriousness and severity of all ae CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing